---
title: How I treat refractory and relapsed acute myeloid leukemia
date: '2023-11-09'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/37944143/?utm_source=curl&utm_medium=rss&utm_campaign=journals&utm_content=7603509&fc=None&ff=20231110170859&v=2.17.9.post6+86293ac
source: Blood
description: The majority of patients with acute myeloid leukemia (AML) develops refractory/relapsed
  (R/R) disease even in the presence of novel and targeted therapies. Given the biological
  complexity of the disease and differences in front-line treatments, there are only
  approved therapies for subgroups of R/R AML and enrollment into clinical trials
  should be first priority. Allogeneic hematopoietic cell transplantation (HCT) is
  the only potentially curative strategy for the majority of ...
disable_comments: true
---
The majority of patients with acute myeloid leukemia (AML) develops refractory/relapsed (R/R) disease even in the presence of novel and targeted therapies. Given the biological complexity of the disease and differences in front-line treatments, there are only approved therapies for subgroups of R/R AML and enrollment into clinical trials should be first priority. Allogeneic hematopoietic cell transplantation (HCT) is the only potentially curative strategy for the majority of ...